Allopurinol - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:58:32Z

Switch SMW query from broadtable to table format for better layout with TOC

← Older revision		Revision as of 21:58, 20 March 2026
Line 61:		Line 61:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Add SMW Indications by Condition query table

2026-03-20T18:20:21Z

Add SMW Indications by Condition query table

← Older revision		Revision as of 18:20, 20 March 2026
Line 51:		Line 51:

	==Comments==		==Comments==

			==Indications by Condition==
			''The following table is automatically generated from disease/condition pages across WikEM.''

			{{#ask:[[Has DrugName::Allopurinol]]
			\|?Has Indication=Indication
			\|?Has Dose=Dose
			\|?Has Context=Context
			\|?Has Route=Route
			\|?Has Population=Population
			\|format=broadtable
			\|headers=plain
			\|mainlabel=-
			\|sort=Has Indication
			\|limit=50
			}}


	==See Also==		==See Also==

ClaireLewis at 16:42, 19 September 2019

2019-09-19T16:42:11Z

← Older revision		Revision as of 16:42, 19 September 2019
Line 6:		Line 6:

	==Adult Dosing==		==Adult Dosing==
	*Gout, nephrolithiasis: 100-300mg PO 1-2 times daily		*[[Gout]], nephrolithiasis: 100-300mg PO 1-2 times daily
	*Tumor lysis syndrome/hyperuricemia in liquid malignancies: 200-800 mg PO or IV daily		*[[Tumor lysis syndrome]]/hyperuricemia in liquid malignancies: 200-800 mg PO or IV daily

	==Pediatric Dosing==		==Pediatric Dosing==
	*<6yo: 150 mg PO daily for 2 to 3 days, then adjust dose for maintenance		*<6yo: 150 mg PO daily for 2 to 3 days, then adjust dose for maintenance
Line 29:		Line 30:
	==Adverse Reactions==		==Adverse Reactions==
	===Serious===		===Serious===
	*Cardiac arrest, ventricular ~~fibrilliation~~, heart failure		*Cardiac arrest, ventricular fibrillation, heart failure
	*SJS/TEN		*SJS/TEN
	*Agranulocytosis, myelosuppression, aplastic anemia, thrombocytopenia, eosinophilia		*Agranulocytosis, myelosuppression, aplastic anemia, thrombocytopenia, eosinophilia
Line 56:		Line 57:
	==References==		==References==
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]] [[Category:Rheumatology]] [[Category:Heme/Onc]]

Humanguy: added dosage forms, added additional trade name

2017-10-11T18:37:22Z

added dosage forms, added additional trade name

← Older revision		Revision as of 18:37, 11 October 2017
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: xanthine oxidase inhibitor		*Type: xanthine oxidase inhibitor
	*Dosage Forms:		*Dosage Forms: tablet, powder for injection
	*Routes of Administration: IV, PO		*Routes of Administration: IV, PO
	*Common Trade Names: Zyloprim		*Common Trade Names: Zyloprim, Aloprim

	==Adult Dosing==		==Adult Dosing==

Mholtz at 05:20, 31 August 2017

2017-08-31T05:20:19Z

← Older revision		Revision as of 05:20, 31 August 2017
Line 3:		Line 3:
	*Dosage Forms:		*Dosage Forms:
	*Routes of Administration: IV, PO		*Routes of Administration: IV, PO
	*Common Trade Names:		*Common Trade Names: Zyloprim

	==Adult Dosing==		==Adult Dosing==

ClaireLewis: Created page with "==Administration== Type: xanthine oxidase inhibitor Dosage Forms: Routes of Administration: IV, PO Common Trade Names: ==Adult Dosing== *Gout, nephrolithiasis: 100-300mg..."

2016-10-05T04:36:01Z

Created page with "==Administration== *Type: xanthine oxidase inhibitor *Dosage Forms: *Routes of Administration: IV, PO *Common Trade Names: ==Adult Dosing== *Gout, nephrolithiasis: 100-300mg..."

New page

==Administration==
*Type: xanthine oxidase inhibitor
*Dosage Forms:
*Routes of Administration: IV, PO
*Common Trade Names:

==Adult Dosing==
*Gout, nephrolithiasis: 100-300mg PO 1-2 times daily
*Tumor lysis syndrome/hyperuricemia in liquid malignancies: 200-800 mg PO or IV daily
==Pediatric Dosing==
*<6yo: 150 mg PO daily for 2 to 3 days, then adjust dose for maintenance
*>6yo: 300 mg PO daily for 2 to 3 days, then adjust dose for maintenance
*200 mg/m(2)/day IV

==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C
*[[Lactation risk categories|Lactation risk]]: Infant risk minimal
===Renal Dosing===
*CrCl 10-20: 200 mg PO or IV daily
*CrCl 3-10: max daily dose 100 mg PO or IV
*CrCl <3: 100mg PO or IV at "extended intervals"
===Hepatic Dosing===
*No adjustment

==Contraindications==
*Allergy to class/drug
*Concomitant use with didanosine

==Adverse Reactions==
===Serious===
*Cardiac arrest, ventricular fibrilliation, heart failure
*SJS/TEN
*Agranulocytosis, myelosuppression, aplastic anemia, thrombocytopenia, eosinophilia
*DIC
*Renal failure
*Respiratory distress
*Hepatotoxicity, granulomatous hepatitis
*Stroke, seizure
===Common===
*Nausea, vomiting
*Rash, pruritus

==Pharmacology==
*Half-life: 1-2 hours
*Metabolism: Hepatic
*Excretion: Renal

==Mechanism of Action==
*Inhibits xanthine oxidase (converts hypoxanthine/xanthine to uric acid), leading to decreased uric acid concentration

==Comments==

==See Also==
*[[Gout]]
*[[Tumor lysis syndrome]]
==References==
<references/>
[[Category:Pharmacology]]